[1] |
Sparber⁃Sauer M, Vokuhl C, Seitz G, et al. Infantile myofibromatosis: excellent prognosis but also rare fatal progressive disease. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry[J]. Pediatr Blood Cancer, 2022,69(3):e29403. doi: 10.1002/pbc.29403.
|
[2] |
Zhao G, Zhu M, Qin C, et al. Infantile myofibromatosis: 32 patients and review of literature[J]. J Pediatr Hematol Oncol, 2020,42(8):495⁃498. doi: 10.1097/MPH.0000000000001603.
|
[3] |
Miller AK, Lashkari N, Pokharel A, et al. Adult⁃onset multifocal cutaneous myofibromas: a case report of a rare entity[J]. Cureus, 2024,16(1):e52438. doi: 10.7759/cureus.52438.
|
[4] |
Saikaly SK, Schoch JJ, Motaparthi K, et al. Generalized infantile myofibromatosis with visceral involvement presenting as diffuse hypopigmented macules at birth[J]. Pediatr Dermatol, 2021,38(1):249⁃252. doi: 10.1111/pde.14456.
|
[5] |
Römer T, Wagner N, Braunschweig T, et al. Aggressive infantile myofibromatosis with intestinal involvement[J]. Mol Cell Pediatr, 2021,8(1):7. doi: 10.1186/s40348⁃021⁃00117⁃9.
|
[6] |
Mashiah J, Hadj⁃Rabia S, Dompmartin A, et al. Infantile myofibromatosis: a series of 28 cases[J]. J Am Acad Dermatol, 2014,71(2):264⁃270. doi: 10.1016/j.jaad.2014.03.035.
|
[7] |
WHO Classification of Tumours Editorial Board. WHO classification of tumours: soft tissue and bone tumours [M]. 5th ed. Lyon:IARC Press, 2020. https://publications.iarc.who.int/Book⁃And⁃Report⁃Series/Who⁃Classification⁃Of⁃Tumours/Soft⁃Tissue⁃And⁃Bone⁃Tumours⁃2020.
|
[8] |
Barry KK, Schienda J, Morrow JJ, et al. Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis[J]. Pediatr Blood Cancer, 2023,70(6):e30262. doi: 10.1002/pbc.30262.
|
[9] |
Machado Morais J, Castro C, Ferraz C, et al. Congenital infantile myofibroma: the importance of molecular diagnosis[J]. Cureus, 2023,15(3):e35885. doi: 10.7759/cureus.35885.
|
[10] |
Iwamura R, Komatsu K, Kusano M, et al. PDGFRB and NOTCH3 mutations are detectable in a wider range of pericytic tumors, including myopericytomas, angioleiomyomas, glomus tumors, and their combined tumors[J]. Mod Pathol, 2023,36(3):100070. doi: 10.1016/j.modpat.2022.100070.
|
[11] |
Hassan M, Butler E, Wilson R, et al. Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib[J]. Cold Spring Harb Mol Case Stud, 2019,5(5):a004440. doi: 10.1101/mcs.a004440.
|
[12] |
Dachy G, Fraitag S, Boulouadnine B, et al. Novel COL4A1⁃VEGFD gene fusion in myofibroma[J]. J Cell Mol Med, 2021,25(9):4387⁃4394. doi: 10.1111/jcmm.16502.
|
[13] |
Yamashita M, Kuroha M, Kinowawki Y, et al. A SAMD5⁃SASH1 fusion in solitary infantile myofibromatosis[J]. Pediatr Blood Cancer, 2023,70(6):e30278. doi: 10.1002/pbc.30278.
|
[14] |
Mehta N, Sahoo D, Gupta AK, et al. Multiple firm erythematous nodules on the scalp of a child[J]. Int J Dermatol, 2020,59(4):425⁃427. doi: 10.1111/ijd.14560.
|
[15] |
Ruiz⁃Arriaga LF, Ramirez Teran AL, Ortiz⁃Hidalgo C, et al. Myopericytoma in an unusual location[J]. Dermatol Online J, 2018,24(4):13030/qt5z02t0dk.
|
[16] |
Braun M, Pascual M, Mully T, et al. Solitary cutaneous infantile myofibroma as a hallmark of myofibromatosis: two cases and review of the literature[J]. Pediatr Dermatol, 2022,39(3):438⁃442. doi: 10.1111/pde.14975.
|
[17] |
Navarro OM. Pearls and pitfalls in the imaging of soft⁃tissue masses in children[J]. Semin Ultrasound CT MR, 2020,41(5):498⁃512. doi: 10.1053/j.sult.2020.05.014.
|
[18] |
付尧, 管文燕, 武海燕, 等. 肌纤维瘤/肌纤维瘤病九例临床病理学分析[J]. 中华病理学杂志, 2018,47(1):45⁃50. doi: 10. 3760/cma.j.issn.0529⁃5807.2018.01.009.
|
[19] |
Iwafuchi H, Tsuzuki T, Ito R, et al. Generalized infantile myofibromatosis with a monophasic primitive pattern[J]. Pathol Int, 2015,65(8):432⁃437. doi: 10.1111/pin.12312.
|
[20] |
Kiyohara T, Maruta N, Iino S, et al. CD34⁃positive infantile myofibromatosis: case report and review of hemangiopericytoma⁃like pattern tumors[J]. J Dermatol, 2016,43(9):1088⁃1091. doi: 10.1111/1346⁃8138.13400.
|
[21] |
晏菲, 孙建海, 朱朋成, 等. 23例肌纤维瘤临床病理观察[J]. 华中科技大学学报(医学版), 2017,46(5):604⁃607,611. doi: 10.3870/j.issn.1672⁃0741.2017.05.022.
|
[22] |
Patel V, Kharkar V, Khopkar U. Adult cutaneous myofibroma[J]. Indian J Dermatol Venereol Leprol, 2008,74(1):56⁃58. doi: 10.4103/0378⁃6323.38412.
|
[23] |
Han JS, Lee MW, Choi JH, et al. Congenital myofibroma mimicking an infantile hemangioma in an infant[J]. Indian J Dermatol, 2014,59(3):317. doi: 10.4103/0019⁃5154.131472.
|
[24] |
Gurley S, Friedman BJ, Shwayder T. Unresectable infantile myofibroma discovered in utero[J]. Pediatr Dermatol, 2024,41(3):558⁃559. doi: 10.1111/pde.15557.
|
[25] |
Lazzara DR, Norris N, Weiss E. Intralesional 5⁃fluorouracil: a therapy for solitary infantile myofibromatosis[J]. Dermatol Surg, 2023,49(4):426⁃427. doi: 10.1097/DSS.0000000000003731.
|
[26] |
El Mansoury FZ, El Yousfi Z, El Farouki A, et al. A rare case of infantile myofibromatosis with intra cranial involvement[J]. Glob Pediatr Health, 2024,11:2333794X241266564. doi: 10.1177/2333794X241266564.
|
[27] |
Manisterski M, Benish M, Levin D, et al. Diverse presentation and tailored treatment of infantile myofibromatosis: a single⁃center experience[J]. Pediatr Blood Cancer, 2021,68(2):e28769. doi: 10.1002/pbc.28769.
|
[28] |
Carruthers V, Barnett S, Rees R, et al. Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: a case series[J]. Pediatr Blood Cancer, 2022,69(7):e29722. doi: 10.1002/pbc.29722.
|
[29] |
Elsbernd A, Boulouadnine B, Ahmed A, et al. Novel oncogenic PDGFRB variant in severe infantile myofibromatosis with response to imatinib using therapeutic drug monitoring[J]. JCO Precis Oncol, 2022,6:e2200250. doi: 10.1200/PO.22.00250.
|
[30] |
Wenger TL, Bly RA, Wu N, et al. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy[J]. Am J Med Genet A, 2020,182(7):1576⁃1591. doi: 10.1002/ajmg.a.61615.
|
[31] |
Bidadi B, Watson A, Weigel B, et al. Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: a case report[J]. Pediatr Blood Cancer, 2020,67(6):e28288. doi: 10.1002/pbc.28288.
|
[32] |
Dachy G, de Krijger RR, Fraitag S, et al. Association of PDGFRB mutations with pediatric myofibroma and myofibromatosis[J]. JAMA Dermatol, 2019,155(8):946⁃950. doi: 10.1001/jamadermatol.2019.0114.
|
[33] |
Pattisapu P, Wenger TL, Dahl JP, et al. Avoidance of surgery for head and neck infantile myofibromatosis using imatinib monotherapy[J]. Clin Case Rep, 2022,10(2):e05382. doi: 10. 1002/ccr3.5382.
|